| Rapivab (peramivir) / BioCryst |
ACTRN12607000282482: To evaluate the effects on time to clinical stability associated with treatment with peramivir administered intravenously compared to oral oseltamivir in adults hospitalized with acute serious or potentially life-threatening influenza |
|
|
| Not yet recruiting | 2 | 120 | | | BioCryst Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc. | Influenza, Life threatening comorbidities suchs as COPD, congestive heart failure and diabetes. | | | | |
ACTRN12607000284460: To evaluate the efficacy of peramivir administered intramuscularly compared to placebo in adult subjects with uncomplicated acute influenza. |
|
|
| Recruiting | 2 | 300 | | | BioCryst Pharmaceuticals Inc, BioCryst Pharmaceuticals Inc. | Uncomplicated influenza. | | | | |
| Completed | 2 | 344 | US, Canada | Peramivir 150 mg, BCX1812, Peramivir 300 mg, Placebo | BioCryst Pharmaceuticals | Influenza | 09/07 | 09/07 | | |
NCT00453999: Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza |
|
|
| Completed | 2 | 137 | US, Canada, RoW | Peramivir 200 mg, Peramivir 400 mg, Oseltamivir | BioCryst Pharmaceuticals | Influenza | 09/08 | 08/09 | | |
NCT00705406: A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza |
|
|
| Completed | 2 | 405 | US, RoW | Peramivir, Placebo | BioCryst Pharmaceuticals | Acute, Uncomplicated Human Influenza | 04/09 | 10/09 | | |
2007-004660-47: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluatethe Virologic Activity, Safety, and Pharmacodynamics of IntravenousPeramivir for the Treatment of Experimental Influenza |
|
|
| | 2 | 51 | Europe | Peramivir, BCX-1812, | BioCryst Pharmaceuticals Inc | Treatment of experimental influenza | | 08/08 | | |
| Recruiting | 2 | 3000 | RoW | Oseltamivir, Favipiravir, Zanamivir, Baloxavir, Molnupiravir, Peramivir, Laninamivir, Oseltamivir and Baloxavir, Oseltamivir and Favipiravir, Favipiravir and Baloxavir | University of Oxford | Influenza, Influenza, Human | 01/27 | 01/27 | | |
NCT01063933: Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza |
|
|
| Withdrawn | 1/2 | 0 | US | Peramivir | National Institute of Allergy and Infectious Diseases (NIAID) | Influenza | 08/11 | 12/12 | | |
